News | June 24, 2009

Microblood Pump Improves Cardiac Function, Myocardial Recovery in Heart Failure Patients

June 24, 2009 – CircuLite Inc. today announced the publication of positive data from its ongoing CE mark clinical trial for the Synergy Pocket Micropump for chronic heart failure in the Journal of the American College of Cardiology.

The data demonstrated that partial circulatory support with Synergy yielded statistically significant long-term improvements in cardiac function, hemodynamic benefits and evidence of myocardial recovery. These results were originally presented in a late-breaking session at the 2009 Annual Meeting of the American College of Cardiology. Synergy is a microblood pump, the size of an AA battery that can be implanted superficially in a pacemaker-like pocket. Synergy is the first and smallest device designed for partial circulatory support (up to 3 L/min) and long-term use in patients with class IIIb and early class IV heart failure.

“Data from the ongoing CE mark trial continue to show that Synergy provides significant hemodynamic benefits to patients and prevents progressive hemodynamic deterioration,” said senior author Daniel Burkhoff, M.D., Ph.D., chief medical officer of CircuLite and adjunct associate professor of medicine at Columbia University Medical School. “Synergy, with its small size and minimally invasive procedure, could result in quality-of-life improvements for patients – CircuLite’s ultimate goal for this device.”

The company is currently pursuing CE mark approval for Synergy and anticipates launching the device in Europe later this year.

At the time of its writing, the article details results for 17 patients (14 males) who were implanted with Synergy. Significant improvements in hemodynamics were observed in the first day of support. Additionally, nine patients had since completed their follow-up right heart catherization at a mean of 10 weeks, and the data demonstrate that the significant hemodynamic improvements were sustained. Mean arterial pressure increased from 67 mmHg to 80 mmHg and mean cardiac index increased from 2 to 2.8 L/min/m2. Large reductions in mean capillary wedge pressure were observed (30 to 18 mmHg). In addition, mean peak VO2 increased from 9.7 to 14.1 ml/kg/minute. The median duration of patient support with Synergy was 81 days, with the longest support period of 213 days. Eighty-two percent (14/17) of patients were alive and nine received heart transplants. The study also demonstrated relatively quick patient recovery following the 90-minute minimally invasive procedure.

The article, titled “Proof of Concept: Hemodynamic Response to Long-Term Partial Ventricular Support with the Synergy Pocket Micro-Pump,” was published in the current print issue of the Journal of the American College of Cardiology (Vol. 53, Issue 26, June 30, 2009).

For more information: www.CircuLite.net

Related Content

FDA Class I Recall Issued for Medtronic HeartWare HVAD Pump
News | Ventricular Assist Devices (VAD) | May 29, 2020
May 29, 2020 — Medtronic is recalling its HeartWare HVAD...
Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...